Navigation Links
MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition
Date:10/26/2007

dImmune continues to reinforce its commitment to developing anti-RSV products with the ongoing development of its next potential anti-RSV antibody, motavizumab, for which the company is planning to submit a Biologic License Application around the beginning of 2008. MedImmune is also developing a small-molecule product candidate to prevent RSV as well as a vaccine against RSV, both of which are in Phase 1 clinical trials.

About RSV

Each year, up to 125,000 infants in the U.S. are hospitalized with severe RSV infections, the leading cause of lower respiratory tract infections in infants in the United States. RSV is the most common respiratory infection in infancy or childhood. Approximately one-half of all infants are infected with RSV during the first year of life, and nearly all children have been infected at least once by the time they reach their second birthday. Children born prematurely as well as those with chronic lung disease (CLD) or congenital heart disease (CHD) are at highest risk for severe disease and hospitalization due to RSV. The virus may also cause severe illness in other high-risk groups such as the elderly, those with underlying respiratory or cardiac disease, and those with compromised immune systems (e.g., bone marrow transplant patients).

About Synagis(R) (palivizumab)

Synagis is the only monoclonal antibody approved by the FDA to help prevent an infectious disease. Synagis is indicated for the prevention of serious lower respiratory tract disease caused by RSV in children at high risk of RSV disease.

Synagis was approved for use in the United States in 1998, Europe in 1999, and Japan in 2002. Synagis is currently available in 62 countries.

The safety and efficacy of Synagis were established in infants with bronchopulmonary dysplasia, infants with a history of prematurity (less than or equal to 35 weeks gestational age), and children with hemodynamically significant congenital heart disease. The first dose o
'/>"/>

SOURCE MedImmune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... CHICAGO , July 29, 2015  AmnioChor Inc., ... cell technology, is very pleased to announce that the ... has agreed to invest in their seed round ... OmniBank placental tissue storage capabilities. AmnioChor,s ... placenta, and the human stem cells living within those ...
(Date:7/29/2015)... SLOUGH, England , July 29, 2015  Indivior ... Application (NDA) for naloxone nasal spray was accepted and ... Administration (FDA) for the treatment of opioid overdose. This ... contains naloxone specially formulated for optimal absorption into the ... to require minimal training so individuals may be better ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - Aeterna Zentaris ... announced it has selected an optimized Erk inhibitor ... in the development of a new class of ... pathway represents a prime target for therapeutic intervention ... activities and survival benefits for B-Raf and Mek ...
(Date:7/29/2015)... ... 2015 , ... Available in select spas and http://www.lespausa.com ... product that targets fat cells for extreme contouring action. During sleep key ingredient ... inhibiting the formation of new fat. Upon waking CHRONODIET breaks down fat cells’ ...
Breaking Biology Technology:The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 2Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 3
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:,ONC, NASDAQ: ONCY) ... Patent 7,300,650 entitled "Reovirus for the Treatment of ... to treat cancers that,have inactivated PKR, whether the ... other factors. PKR is a host cellular protein ...
... Xenome Ltd, a specialist,biopharmaceutical company developing ... successfully raised US$10M of equity finance. The ... major investor,Queensland BioCapital Funds (QBF), for $2.7M, ... Inc, a top tier USA biotechnology company,headquartered ...
... Geffen School of Medicine at UCLA and the Howard ... largest cellular particle ever crystallized, suggesting ways to engineer ... The research study, which focuses on new engineered nanomaterial ... the Nov. 27 edition of the peer-reviewed, open-access journal ...
Cached Biology Technology:Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent 2Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners 2Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners 3Researchers outline structure of largest nonvirus particle ever crystallized 2
(Date:7/8/2015)... Florida , July 8, 2015 ... evolving as this summer,s must have products such as wearables, ... demand as popularity for biometrics based devices continues to rapidly ... NXT-ID, Inc. (NASDAQ: NXTD ), Google Inc. (NASDAQ: ... (NYSE: FIT ), GoPro, Inc. (NASDAQ: GPRO ) ...
(Date:7/2/2015)... , June 25, 2015 ... announced the addition of the "Natural Language ... Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) ... their offering. The key vendors occupying ... HP, IBM Corporation, Microsoft Corporation, NetBase Solutions, SAS ...
(Date:6/30/2015)... Genisphere announced Tom Bliss ... further develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss ... much of the last 25 years in leadership positions ... Johnson & Johnson. Tom started his career in Investment ... Finance. He graduated from Dartmouth College with a BA ...
Breaking Biology News(10 mins):Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
... transboundary water systems is the focus of a wide-ranging ... of the Elsevier journal Environmental Development . ... and the UN University,s Canadian-based Institute for Water, Environment ... of articles available with open public access until the ...
... charities, volunteer to clean up city parks, or scale back ... public goods for granted and ride free on the efforts ... donation to fund it. Or they run their lawn sprinklers ... limit water consumption. A new report in Psychological ...
... like a temporary tattoo, can alert marathoners, competitive bikers and ... the wall," scientists are reporting. The study, in ACS, journal ... the sensor, which also could help soldiers and others who ... stamina and fitness. Joseph Wang and colleagues explain ...
Cached Biology News:Managing waters shared across national boundaries: Treasury of papers helps capture 20 years of lessons 2Managing waters shared across national boundaries: Treasury of papers helps capture 20 years of lessons 3Managing waters shared across national boundaries: Treasury of papers helps capture 20 years of lessons 4Managing waters shared across national boundaries: Treasury of papers helps capture 20 years of lessons 5Trust in leaders, sense of belonging stir people to safeguard common goods, analysis shows 2Trust in leaders, sense of belonging stir people to safeguard common goods, analysis shows 3
Harmful, Irritant, Combustible ,DEPC...
Permeabilization Solution, 5X...
Cytofix/Cytoperm Plus Kit with GolgiPlug 250 Tests...
Mouse monoclonal to OCIL ( Abpromise for all tested applications)....
Biology Products: